Vortioxetine for the treatment of major depression
Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved..
Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of major depression and generalized anxiety disorders. Vortioxetine has a unique "multi-modal" mechanism of action. It inhibits the activity of serotonin transporters and is an agonist of serotonin 5-HT1A receptor, partial agonist of 5-HT1B and antagonist of 5-HT3A, 5-HT7 and 5-HT1D receptors. Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day. Vortioxetine reverses cognitive decline in patients with depression making it a unique molecule. The molecule lacks any serious side effects and drug-drug interactions. However, dose adjustments are required if vortioxetine is co-administered with rifampicin or bupropion. The molecule is under review by various regulatory agencies around the world for the treatment of major depression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 49(2013), 12 vom: 04. Dez., Seite 781-90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dhir, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3O2K1S3WQV |
|---|
| Anmerkungen: |
Date Completed 10.03.2014 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2013.49.12.2058448 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM235414697 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM235414697 | ||
| 003 | DE-627 | ||
| 005 | 20231224103342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2013.49.12.2058448 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0784.xml |
| 035 | |a (DE-627)NLM235414697 | ||
| 035 | |a (NLM)24524096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dhir, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vortioxetine for the treatment of major depression |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2014 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved. | ||
| 520 | |a Vortioxetine (Lu-AA-21004; 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine hydrobromide) is a novel orally active molecule that is being investigated by Lundbeck and Takeda for the treatment of major depression and generalized anxiety disorders. Vortioxetine has a unique "multi-modal" mechanism of action. It inhibits the activity of serotonin transporters and is an agonist of serotonin 5-HT1A receptor, partial agonist of 5-HT1B and antagonist of 5-HT3A, 5-HT7 and 5-HT1D receptors. Vortioxetine has been effective in various animal models of depression and anxiety and clinical studies have shown the antidepressant and antianxiety properties of vortioxetine in a dose range of 5-20 mg/day. Vortioxetine reverses cognitive decline in patients with depression making it a unique molecule. The molecule lacks any serious side effects and drug-drug interactions. However, dose adjustments are required if vortioxetine is co-administered with rifampicin or bupropion. The molecule is under review by various regulatory agencies around the world for the treatment of major depression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 5-HT reuptake inhibitor | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Lu-AA-21004 | |
| 650 | 4 | |a Major depression | |
| 650 | 4 | |a Vortioxetine hydrobromide | |
| 650 | 7 | |a Anti-Anxiety Agents |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Piperazines |2 NLM | |
| 650 | 7 | |a Sulfides |2 NLM | |
| 650 | 7 | |a Vortioxetine |2 NLM | |
| 650 | 7 | |a 3O2K1S3WQV |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 49(2013), 12 vom: 04. Dez., Seite 781-90 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2013 |g number:12 |g day:04 |g month:12 |g pages:781-90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2013.49.12.2058448 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2013 |e 12 |b 04 |c 12 |h 781-90 | ||